Dr. Lal PathLabs Limited reported a strong financial performance for the second quarter of FY27, with consolidated net profit increasing 27.4% year-on-year (YoY) to approximately ₹194 crore, compared with ₹152 crore in the corresponding quarter of the previous financial year.
The diagnostic services provider’s revenue from operations grew 19.6% YoY to ₹873.9 crore in Q2 FY27, against ₹730.6 crore in Q2 FY26. The performance was supported by higher testing volumes and increased demand for diagnostic services.
The company’s consolidated total income stood at ₹908.2 crore during the quarter, registering a growth of 20.2% compared with ₹755.4 crore in the year-ago period.
Dr. Lal PathLabs Q2 Results : EBITDA Increases 25.1%
Dr. Lal PathLabs recorded EBITDA of approximately ₹280 crore in Q2 FY27, marking an increase of 25.1% from around ₹224 crore in the corresponding quarter last year.
The EBITDA margin improved to 32.1% from 30.7% in Q2 FY26, reflecting an expansion of approximately 140 basis points. The growth in EBITDA outpaced revenue growth during the quarter.
Profit before tax increased 27.9% YoY to approximately ₹260.5 crore, compared with ₹203.6 crore in the corresponding quarter of the previous financial year.
Testing Volumes Support Quarterly Performance
The company’s operational performance also recorded growth during the September quarter. Sample volumes increased 13.6% year-on-year, while patient volumes grew 9%.
The company continues to focus on scientific excellence, network expansion, technology-led patient engagement and the development of specialised diagnostic services. Its focus areas include advanced testing capabilities in genomics, oncology and other high-complexity diagnostic segments.
Dr. Lal PathLabs Declares ₹5 Second Interim Dividend
Alongside its quarterly results, the company’s Board of Directors declared a second interim dividend of ₹5 per equity share for FY27. The dividend represents 50% of the share’s face value of ₹10.
The company fixed November 11, 2026, as the record date to determine eligible shareholders. The dividend is expected to be paid within 30 days of its declaration.
Dr. Lal PathLabs H1 FY27 Performance
For the first half of FY27, Dr. Lal PathLabs reported revenue of approximately ₹1,672 crore, registering growth of 19.4% compared with ₹1,400 crore in H1 FY26.
EBITDA increased 26.7% to approximately ₹528 crore, while profit after tax rose 27.3% to around ₹364 crore during the six-month period.
Dr. Lal PathLabs Q2 FY27: Key Financial Highlights
- Revenue from operations: ₹873.9 crore, up 19.6% YoY.
- Total income: ₹908.2 crore, up 20.2% YoY.
- EBITDA: Approximately ₹280 crore, up 25.1% YoY.
- EBITDA margin: 32.1%, compared with 30.7% in Q2 FY26.
- Net profit: Approximately ₹194 crore, up 27.4% YoY.
- Second interim dividend: ₹5 per equity share.
Dr. Lal PathLabs’ Q2 FY27 performance reflects growth across revenue, operating earnings and profitability, supported by higher testing volumes and increased patient activity. The dividend announcement was another key decision taken by the board during the results meeting.
Source: Dr. Lal PathLabs’ Q2 and H1 FY27 financial results and earnings disclosures filed with the BSE on November 4, 2026.
Disclaimer: Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
If you want to know which upcoming Q2 earnings reports are dropping? Check out Upcoming Q2 Results
Do you have a news tip for Lakshmishree reporters? Please email us at [email protected]
News Desk
